Bio Medica Laboratories (NSE:BMLL) ROC (Joel Greenblatt) %: 63.98% (As of Mar. 2025) — 92% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BMLL Bio Medica Laboratories Ltd NSE:BMLL
18 GF Score
Price ₹146.80
! 7 Warning Signs
View Full Analysis

What is Bio Medica Laboratories ROC (Joel Greenblatt) %?

Bio Medica Laboratories NSE:BMLL +1.21% 18 ROC (Joel Greenblatt) % is 63.98% as of Mar. 2025, which is 92% above its 10-year median of 33.27. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 92% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bio Medica Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 63.98%.

The historical rank and industry rank for Bio Medica Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:

NSE:BMLL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.71   Med: 33.27   Max: 63.98
Current: 63.98

During the past 3 years, Bio Medica Laboratories's highest ROC (Joel Greenblatt) % was 63.98%. The lowest was 9.71%. And the median was 33.27%.

NSE:BMLL's ROC (Joel Greenblatt) % is ranked better than
92% of 838 companies
in the Medical Devices & Instruments industry
Industry Median: 4.64 vs NSE:BMLL: 63.98

Bio Medica Laboratories's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Bio Medica Laboratories  (NSE:BMLL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Bio Medica Laboratories ROC (Joel Greenblatt) % Related Terms


Bio Medica Laboratories ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Bio Medica Laboratories's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories ROC (Joel Greenblatt) % Chart

Bio Medica Laboratories Annual Data
Trend Mar23 Mar24 Mar25
ROC (Joel Greenblatt) %
9.71 33.27 63.98

Bio Medica Laboratories Semi-Annual Data
Mar23 Mar24 Mar25
ROC (Joel Greenblatt) % 9.71 33.27 63.98

NSE:BMLL vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison

For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio Medica Laboratories ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Bio Medica Laboratories's ROC (Joel Greenblatt) % falls into.


NSE:BMLL
18GF Score
Bio Medica Laboratories Ltd NSE:BMLL
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio Medica Laboratories ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.359 + 73.669 + 8.386) - (24.624 + 0 + 13.694)
=67.096

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(41.002 + 181.379 + 88.463) - (51.72 + 0 + 35.728)
=223.396

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Bio Medica Laboratories for the quarter that ended in Mar. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=144.702/( ( (87.271 + max(67.096, 0)) + (74.605 + max(223.396, 0)) )/ 2 )
=144.702/( ( 154.367 + 298.001 )/ 2 )
=144.702/226.184
=63.98 %

Note: The EBIT data used here is one times the annual (Mar. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 63.98% mean?
Bio Medica Laboratories (NSE:BMLL) has a ROC (Joel Greenblatt) % of 63.98% as of Mar. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bio Medica Laboratories and its competitors. This is 92% above median its historical median of 33.27. Over the past decade, Bio Medica Laboratories' ROC (Joel Greenblatt) % has ranged from 9.71 to 63.98. According to the industry distribution chart, Bio Medica Laboratories ranks #67 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Bio Medica Laboratories' ROC (Joel Greenblatt) % too high?
Bio Medica Laboratories' current ROC (Joel Greenblatt) % of 63.98% is 92% above median its 10-year median of 33.27. Over the past 10 years, this metric has ranged from a low of 9.71 to a high of 63.98. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.64. Bio Medica Laboratories' value of 63.98% is 1278.9% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #67 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #67 out of 838 companies for ROC (Joel Greenblatt) %. This places Bio Medica Laboratories in the top 8% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.64. Bio Medica Laboratories' value of 63.98% is 1278.9% above this benchmark. Historically, Bio Medica Laboratories' own ROC (Joel Greenblatt) % has ranged from 9.71 to 63.98 over the past decade. While the company's 10-year median is 33.27 vs. the industry median of 4.64, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.64, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current ROC (Joel Greenblatt) % of 63.98% is 1278.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current ROC (Joel Greenblatt) % is 63.98%, which is 92% above median its own 10-year median of 33.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current ROC (Joel Greenblatt) % of 63.98%. The current ROC (Joel Greenblatt) % is 63.98%, which is 92% above median its 10-year median of 33.27 and 1278.9% above the Medical Devices & Instruments industry median of 4.64. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current ROC (Joel Greenblatt) % is 63.98% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Medica Laboratories Business Description

Address Sanwer Road, Plot No. 11B-11C, Sector-E, Industrial Area, Industrial Estate - Indore, Indore, MP, IND, 452015
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score

Get the complete analysis for NSE:BMLL

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹146.80
Price